公开(公告)号：EP1463727A2

公开(公告)日：2004-10-06

申请号：EP02767146.0

申请日：2002-09-19

申请人： NOVO NORDISK A/S

发明人： KANSTRUP, Anders, B. ,  SAMS, Christian, Klarner ,  LUNDBECK, Jane, Marie ,  CHRISTIANSEN, Lise, Brown ,  BOWLER, Andrew, Neil

IPC分类号： C07D473/02 ,  A61K31/522

CPC分类号： C07D473/06 ,  C07D473/04

摘要： The present invention relates to therapeutically active and selective inhibitors (Formula II)of the enzyme DPP-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated with proteins that are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity. The present inhibitors are novel purine derivatives, attached at position 8 of the purine skeleton to a diamine.

公开(公告)号：EP1404675B1

公开(公告)日：2008-03-12

申请号：EP02748629.9

申请日：2002-06-27

申请人： NOVO NORDISK A/S

发明人： KANSTRUP, Anders, Bendtz ,  SAMS, Christian, Klarner ,  LUNDBECK, Jane, Marie ,  CHRISTIANSEN, Lise, Brown ,  KRISTIANSEN, Marit

IPC分类号： C07D473/08 ,  A61K31/522 ,  A61P3/10

CPC分类号： C07D473/00 ,  C07D473/02

摘要： The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV of formula I, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated with proteins that are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity. (I)

公开(公告)号：EP1404675A1

公开(公告)日：2004-04-07

申请号：EP02748629.9

申请日：2002-06-27

申请人： NOVO NORDISK A/S

发明人： KANSTRUP, Anders, Bendtz ,  SAMS, Christian, Klarner ,  LUNDBECK, Jane, Marie ,  CHRISTIANSEN, Lise, Brown ,  KRISTIANSEN, Marit

IPC分类号： C07D473/08 ,  A61K31/522 ,  A61P3/10

CPC分类号： C07D473/00 ,  C07D473/02

摘要： The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV of formula I, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated with proteins that are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity. (I)